BrainStorm Cell Therapeutics has announced that its NurOwn (MSC-NTF cell) derived exosomes provided significant improvement in lung function and histology in an acute respiratory distress syndrome (ARDS) mouse model, in a preclinical study.

Mesenchymal stem cell (MSC)-derived exosomes can penetrate deep into tissues and deliver immunomodulatory molecules effectively.

A type of respiratory failure, ARDS is linked to Covid-19 and is mediated by dysregulated cytokine production.

Intratracheal administration of NurOwn derived exosomes provided a statistically significant reduction in lung disease severity score, the study data showed.

Furthermore, improvements in lipopolysaccharide (LPS)-induced ARDS markers like lung function, fibrin presence, neutrophil accumulation, cytokine expression and oxygenation levels in the blood, were observed.

These improvements were significantly superior to those noticed following nave MSC-derived exosome administration.

BrainStorm Research and Development vice-president Dr Revital Aricha said: These exciting preclinical data suggest that NurOwn derived exosomes have the potential to treat Covid-19-induced ARDS or other severe respiratory complications and that they are more effective than exosomes isolated from nave MSCs at combatting the various symptoms of the syndrome.

This publication in a highly regarded journal provides important validation for the scientific advances and significance of BrainStorms preclinical research programs, including on our exosome-based technology platform.

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.

MSC-NTF cells are made from autologous, bone marrow-derived MSCs expanded and separated ex vivo.

Brainstorm CEO Chaim Lebovits said: While our primary focus is on advancing NurOwn towards regulatory approval in ALS, we continue to evaluate the potential of our exosome-based platform to address unmet medical needs.

In December 2019, the company received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase II clinical trial of NurOwn in progressive multiple sclerosis patients.

Global Real Time Tracking and Monitoring Solutions for Clinical trials

28 Aug 2020

Software, Consulting and Workshops for Data Analysis and Model-Based Decision Support

28 Aug 2020

See the original post here:
BrainStorm's Covid-19 ARDS treatment improves lung function in study - Clinical Trials Arena

Recommendation and review posted by Bethany Smith

Large pharmaceutical companies have made gene therapy a priority with a series of acquisitions over the past several years, a stamp of validation for a field that's pushed through decades of ups and downs.

One of the latest buyers is German healthcare conglomerate Bayer, which in October inked a $2 billion deal for North Carolina gene therapy developer Asklepios Biopharmaceuticals, also known as AskBio.

For Bayer, the acquisition is part of a broader effort to build a gene and cell therapy division. But the deal is just as noteworthy for AskBio, an unusually large, privately held biotech based on the work of one of gene therapy's pioneers, Jude Samulski.

AskBio chose the security of a wealthy backer over independence and the chance to go public like several of its peers. And the deal helped the biotech quickly hire Katherine High, one of the few executives with experience shepherding a gene therapy through to regulatory approval. All of which makes the efforts of AskBio, now operating as an independent arm of Bayer, worth watching.

"I think we have the right people, the right chemistry, and the right amount of experience to make a difference here," Samulski said in an interview.

As 2019 drew to a close, so did a chapter in High's career. A hematologist by training, High, 69, has spent three decades working in gene therapy, a large portion of which was as a founder, president and chief scientific officer of Philadelphia biotech Spark Therapeutics.

At Spark, High had helped make history by steering the development of Luxturna, a treatment for a genetic form of blindness. When cleared by the Food and Drug Administration in late 2017, Luxturna became the first gene therapy for an inherited disease approved in the U.S. Roche swooped in soon after to acquire Spark, and closed the deal in December 2019.

Katherine High, president of therapeutics at AskBio

Permission granted by AskBio

High decided to take a year off from biopharma. But the coronavirus pandemic dashed her plans to conduct research at Rockefeller University. The institution reduced its staff to essential personnel, and the Harvard Club of New York City, where High, a Philadelphia resident, planned to stay during the week, closed its doors.

"My sabbatical turned into a virtual event, which was good; I got a lot of things done review articles written, book chapters written, things like that," High said in an interview. "I really needed a break."

She spent time with her first grandchild, swam, and, fulfilling a longtime desire, remotely studied German at Middlebury College's storied language program.

But High couldn't keep away from drug research. During periodic visits to North Carolina, where she has family, High dropped in on Samulski and fellow AskBio co-founder Sheila Mikhail.

High has over the years both collaborated and competed with Samulski, a University of North Carolina researcher and expert in gene therapy delivery tools known as adeno-associated viruses, or AAVs. He formed AskBio in 2001 with another gene therapy researcher, Xiao Xiao, and CEO Sheila Mikhail, a life sciences attorney.

"Our paths have crossed, our students have crossed, our sciences [have] definitely cross-pollinated," Samulski said, describing High's academic work at University of Pennsylvania and his at UNC.

By the time of their meeting, AskBio had grown to become one of the gene therapy field's most unique. Originally bootstrapped with angel investing and backing from the Muscular Dystrophy Association, AskBio had spun multiple gene therapy programs into companies that were later acquired. The returns from those buyouts were then used by AskBio to build its own manufacturing capabilities, a crucial step for gene therapy products.

During High's visits, Samulski and Mikail shared some of the progress the company had made advancing its technology. Among them: the acquisition of a Scottish biotech whose technology may allow the company to more tightly control how much protein a gene therapy can produce. Doing so could help overcome a critical limitations of gene therapy, which can have widely varying effects from patient to patient.

"We have a roadmap, how to get from A to B," Samulski told High. "If you want to come in and champion that, we would love to have you."

As AskBio was courting High, Bayer was eyeing AskBio, which had put in motion plans for an initial public offering a typical step for a biotech of its size.

Bayer had already announced plans to develop a cell and gene therapy division, acquiring Bluerock Therapeutics, a maker of "off-the-shelf" cell-based treatments, in 2019.

But the large pharma didn't have an anchor for its gene therapy ambitions. Marianne De Backer, Bayer's head of business strategy and development, had assembled a list of developers to pursue. AskBio was at the top.

"If you look at the [gene therapy] assets that are on the market today, like Zolgensma from Novartis, part of the technology is based on technology from AskBio," she said in an interview, referring to the Swiss company's spinal muscular atrophy treatment. A Duchenne muscular dystrophy treatment in late-stage testing at Pfizer also originated within AskBio, as did a Takeda program being studied in hemophilia.

De Backer faced two obstacles, though. Bayer, for one, didn't know the AskBio team, and couldn't meet them in person because of the travel restrictions that began during the pandemic.

"It was really almost a cold call," she said.

Bayer was also competing against the draw of a deep market for public stock offerings, which helped a record number of biotechs to IPO in 2020. De Backer said she needed to show AskBio that she could get the deal done quickly. So she and Mikhail spent six weeks hammering out terms, including an agreement the company could continue to operate independently an "arm's length" arrangement like one Bayer made with BlueRock.

Such promises are often made, and eventually broken, when a larger company acquires a smaller one. But Samulski's concerns that AskBio's work might be stifled within such a massive company were eased after speaking with BlueRock CEO Emile Nuwaysir.

Jude Samulski, co-founder and chief scientific officer at AskBio

Permission granted by AskBio

"[Nuwaysir] said, they have left me alone, they've encouraged me to do what I'm doing,' and I said, OK, that's what I needed to hear,'" Samulski said.

The acquisition allows the company to spend more time on science and less on raising money, he added.

"If I go back and write a grant today, it'll be three years before we can start the project," Samulski said. "In this setting, when we have our meeting ... the decision-makers are at the table and the science starts that afternoon."

For High, AskBio represents a return to a similar role as the one she had left: helping run an advanced gene therapy business newly acquired by big pharma. At AskBio, she's been named president of therapeutics.

The role, however, lines up with High's current career ambitions. AskBio has the manufacturing capabilities, breadth of clinical-stage programs and financial backing to take on diseases like Parkinson's and congestive heart failure the types of complex, common conditions gene therapy hasn't yet been proven in.

"There are great strengths in pharma, and there are great strengths in biotech, and the ideal situation is one that will let you employ the strengths of both types of organizations," she said.

High considered other options, such as working with a different and unproven drugmaking technology. But as someone who's spent much of her life living the story of gene therapy, she knows more than most the challenges of pioneering a new technology and convincing regulators of its worth.

Sometimes people "may underestimate the amount of time it takes to build all the tools that you need to enable regulators to say 'yes, this is safe,'" she said.

By sticking with gene therapy, much of the groundwork has been laid. She's just looking to take it a step further.

"I'm probably not going to work for another three decades," High said, with a laugh.

Read this article:
How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division - BioPharma Dive

Recommendation and review posted by Bethany Smith

However, the partners were not willing to disclose, as of today, which diseases exactly are being targeted under this alliance.

The collaborative project combines Neurogenes manufacturing and drug development capabilities with the University of Edinburghs novel platform and neurodevelopmental disease expertise.

Under the terms of the collaboration, the US company will provide financial support for Dr Stuart Cobbs laboratory at the University of Edinburgh, in exchange for the right to license any applicable intellectual property at agreed-upon economic terms.Neurogene will be responsible for late stage preclinical and all clinical development of any products generated under the collaboration.

Dr Cobbs lab uses a broad range of technologies to develop novel treatments for neurodevelopmental disorders based on a deep understanding of the molecular pathology.

In addition to Dr Cobbs position at the university, where he is a Simons fellow and reader in neuroscience, he is also Neurogenes chief scientific officer (CSO).

Neurogenes lead programs use adeno-associated virus (AAV) vector-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Its product pipeline of gene therapy candidates addresses distinct monogenic neurological diseases.

Neurogene is trying to find treatments for, among others, Batten disease - a group of rare, inherited diseases of the nervous system also called neuronal ceroid lipofuscinoses (NCLs).The company is focusing on CLN5 and CLN7, two rare, late infantile and rapidly progressive subtypes of Batten disease.Children with CLN5 or CLN7 typically develop signs and symptoms of the diseases at a young age, including seizures, progressive deterioration in intellectual and motor capabilities, and loss of vision.CLN5 is caused by a variant in the CLN5 gene, which leads to disruption of normal CLN5 protein function. The CLN7 subtype of Batten disease is caused by a variant in the CLN7 gene, also called the MFSD8 gene, which leads to disruption of normal CLN7 protein function.

Another disorder Neurogene is targeting is Charcot-Marie-Tooth disease (CMT) a group of inherited diseases that affect the peripheral nervous system (PNS). CMTs are the most common inherited motor and sensory nerve disorders - neuropathies.

It is also working to determine and address the root cause of diseases such as aspartylglucosaminuria (AGU) a rare, neurodegenerative lysosomal storage disorder (LSD).

In December 2020, Neurogene announced the completion of a US$115m Series B financing, which was led by EcoR1 Capital, with participation from existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed leading healthcare investment fund.

New investors included funds and accounts managed by BlackRock, funds managed by Janus Henderson Investors, Casdin Capital, Avidity Partners, Ascendant BioCapital, Arrowmark Partners, and Alexandria Venture Investments.

The company said proceeds from the financing would be used to advance Neurogenes portfolio of multiple gene therapy programs into the clinic, as well as accelerate investment in novel gene therapy product designs and Neurogenes technology platform addressing key limitations in conventional gene therapy, while building out its AAV vector GMP manufacturing capabilities.

Oleg Nodelman, portfolio manager, EcoR1 Capital, said then: Neurogene is establishing itself as a leader in the gene therapy arena for neurological diseases. We are impressed by the companys innovation and accomplishments to date and are pleased to provide our support to Neurogene to advance medical research in this rapidly evolving area.

Visit link:
Neurogene in tie up with university to advance gene therapy technologies - BioPharma-Reporter.com

Recommendation and review posted by Bethany Smith

Jan. 22, 2021, FNF Research (fnfresearch.com) published the latest study on [2020-2026] Cell and Gene Therapy Consumables Market Report by Quantitative Research Incorporating Impact Of Economic And Non-economic Aspects was recently released. It uses exploratory techniques like qualitative and quantitative analysis to uncover and present data on the target market. Efficient sales strategies have been mentioned that would business and multiply customers in record time.

This report is presented in a clear and concise way to help you better understand market structure and dynamics. Recent trends and developments in the Cell and Gene Therapy Consumables Market have been analyzed. Opportunities leading to market growth have been analyzed and stated. The report focuses on the global market and provides answers to the most important questions that stakeholders are facing today in the world. Information on the size of the market raises the issue of expanding competitiveness and hindering market-leading sectors and market growth.

Request an Exclusive Free Sample Copy of Research Report of Cell and Gene Therapy Consumables Market: https://www.fnfresearch.com/sample/cell-and-gene-therapy-consumables-market-by-product-107

(The sample of this report is readily available on request).

The FREE Sample Report Includes:

Key Questions Answered in this Report

The report also features information about significant market players across global regions that are North America, Europe, Latin America, Asia Pacific, and India. This further helps to enlighten the strong and effective business outlook of the industrial global expanse. Apart from paying attention to the present competitive current market scenario, the report also shares knowledge on the growth prospects of global Cell and Gene Therapy Consumables market during the forecast period of 2020-2026. The report also contains a circumstantiated description of various key vendors that are operating in the global regions. Showcasing a cosmopolitan landscape of Cell and Gene Therapy Consumables sector, the report marks the prevalent industry competition that is visible on both domestic as well as the global level.

The report provides:

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.fnfresearch.com/inquiry/cell-and-gene-therapy-consumables-market-by-product-107

Competition Analysis

The global Cell and Gene Therapy Consumables market is divided on the basis of domains along with its competitors. Drivers and opportunities are elaborated along with their scope that helps to boosts the performance of the industries. It throws light on different leading key players to recognize the existing outline of Cell and Gene Therapy Consumables market. This report examines the ups and downs of the leading key players, which helps to maintain proper balance in the framework. Different global regions, such as Germany, South Africa, Asia Pacific, Japan, and China are analyzed for the study of productivity along with its scope. Moreover, this report marks the factors, which are responsible to increase the number of patrons at domestic as well as global level.

The Cell and Gene Therapy Consumables market is expected to grow in the upcoming 2020 to 2027 year. Different risks are considered, which helps to evaluate the complexity in the framework. The progress rate of global industries is mentioned to give a clear picture of business approaches. Various factors, which are responsible for the growth of the market are mentioned accurately. It gives a detailed description of drivers and opportunities in Cell and Gene Therapy Consumables market that helps the consumers and potential customers to get a clear vision and take effective decisions. Different analysis models, such as Cell and Gene Therapy Consumables are used to discover the desired data of the target market. In addition to this, it comprises various strategic planning techniques, which promote the way to define and develop the framework of the industries.

Regional outlook:

As per the research study by FNF Market Research, the global Cell and Gene Therapy Consumables market has fragmented across several regions such as North America, Latin America, Asia-Pacific, Africa, and Europe on the basis of key players. It covers the broad analysis of regional business overview including the financial overview.

Major industry key players have been documented to study successful strategies employed by leading industries.

Amgen Inc.

ATLANTA BIOLOGICALS

bluebird bio Inc.

Cook

Dendreon Pharmaceuticals LLC

Fibrocell Science Inc.

General Electric

Kolon TissueGene Inc.

Orchard Therapeutics plc.

Pfizer Inc.

PromoCell GmbH

RENOVA THERAPEUTICS

Sibiono GeneTech Co. Ltd.

Spark Therapeutics Inc.

Vericel

Helixmith Co. Ltd.

Vitrolife

Different market factors such as type, size, applications, and end-users have been included to study businesses thoroughly. Major pillars of the businesses that affect the ups and downs of Cell and Gene Therapy Consumables companies are also included in this report. The study has been aggregated on the basis of recent scope, challenges faced by businesses, and global opportunities to enlarge the Cell and Gene Therapy Consumables sector in upcoming years.

Reasons to Purchase this Report:

Browse detailed report with in-depth TOC HERE: https://www.fnfresearch.com/cell-and-gene-therapy-consumables-market-by-product-107

Global competitive landscape:

To offer a holistic snapshot of global competition, different leading industry key players have been profiled to get better insights about the strategies adopted by them. The notable feature of this research report is, it gives more focus on strategies to discover the potential customers and to identify the global customers to enlarge the businesses.

In the event that you dont find that you are looking in this report or need any particular prerequisites, please get in touch with our custom research team at sales@fnfresearch.com

Any special requirements about this report, please let us know and we can provide a custom report.

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing a planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email: sales@fnfresearch.com

Web: https://www.fnfresearch.com

Follow this link:
Cell and Gene Therapy Consumables Market 2020 Key Manufacturers, Development Trends and Competitive Analysis 2026 KSU | The Sentinel Newspaper - KSU...

Recommendation and review posted by Bethany Smith

Researchers have implicated the pro-inflammatory cytokine interleukin-1 (IL-1) in a wide variety of diseases such as osteoarthritis, rheumatoid arthritis (RA), diabetes, and obesity. Steven Abramson, MD, the Frederick H. King Professor of Internal Medicine, professor of pathology, and chair of the Department of Medicine at NYU Langone Health, has long studied how IL-1 can propagate and exacerbate the disease process. That research effort has more recently expanded to include investigations into how the anti-inflammatory IL-1 receptor antagonist, IL-1Ra, can counter IL-1 and modulate the inflammatory response. Based on intriguing findings about how certain gene variants may influence osteoarthritis risk and severity, a new National Institutes of Health (NIH) research grant will help Dr. Abramson and collaborators seek out IL-1related targets for inflammatory disease prevention and treatment.

To help clarify the inflammatory process, Dr. Abramson and collaborators including Mukundan G. Attur, PhD, associate professor of medicine, and Jonathan Samuels, MD, associate professor of medicine, examined several variants of the IL-1Raencoding IL1RN gene in the knee joints and cells of osteoarthritis and rheumatoid arthritis patients. In particular, a haplotype designated TTG predicted which at-risk patients would go on to develop knee osteoarthritis and was associated with more severe radiographic osteoarthritis as well as new onset RA. Its a marker of both severity and increased risk for incident osteoarthritis, Dr. Abramson says.

Their 2019 study in osteoarthritis patients, published in Annals of the Rheumatic Diseases, suggested that the IL1RN TTG haplotype produced less IL-1Ra protein. So one explanation for the finding is that these people with the gene are deficient in the endogenous inhibitor of IL-1, which is driving the disease, Dr. Abramson says. Conversely, a separate haplotype called CTA yields more IL-1Ra protein production and may be protective.

In collaboration with Jef D. Boeke, PhD, professor of biochemistry and molecular pharmacology and director of the Institute for Systems Genetics, a new NIH grant may help clarify how each gene haplotype modulates inflammation, influences the associated gene regulatory networks, and contributes to the mechanics of disease pathogenesis. In particular, the research will focus on a haplotype block, or a section of DNA including multiple genes adjacent to the IL1RN gene. The researchers hope to learn whether any of the neighboring genes have inflammatory properties of their own, a synergistic effect on IL1RN, or even a more dominant effect on the underlying inflammatory pathway. One reason to do that is if youre developing a drug, you might find that one of these other genes is a better target than IL1RN, Dr. Abramson says.

One key to the unique research effort is Dr. Boekes expertise in using CRISPR-Cas9 gene editing technology to construct a series of what his lab calls assemblons, or precisely altered haplotype blocks. Led by Dr. Attur, the collaborators will then transfect embryonic stem cells with the manipulated DNA and use in vitro assays to gauge the effects of the putative risk and protective IL1RN haplotypes. The genetic manipulation is very technical. But if we can succeed, it allows us to really define the role of these haplotypes, not just in osteoarthritis but in other IL-1driven diseases, Dr. Abramson says.

After differentiating the engineered embryonic stem cells into macrophage cells, the researchers will measure production of the IL-1Ra protein. Well also be stimulating the macrophages in an inflammatory way and looking at the profile of inflammatory mediators that they produce, Dr. Abramson says. Experiments may reveal whether stimulated macrophages that carry the protective IL1RN CTA haplotype, for example, produce more IL1-Ra protein and fewer pro-inflammatory mediators such as IL-1, cyclooxygenase-2 (COX-2), and tumor necrosis factor (TNF). In the same way, sequential knockouts of other genes in the assemblon may clarify their own contributions to each haplotypes effects.

If the researchers can zero in on the principal drivers of disease through their in vitro experiments, they plan to inject the engineered embryonic stem cells into mice models of osteoarthritis and RA. The in vivo studies of the gene regulatory network may help determine how specific gene variants influence disease outcomes.

The research could have broad implications for understanding IL-1associated inflammatory diseases and for personalizing antiIL-1 therapies. It might be that in personalized medicine, antiIL-1 treatments will be more effective in patients who have a deficiency of IL-1 receptor antagonist, Dr. Abramson says. A patient who produces abundant IL-1Ra, on the other hand, may not benefit from receiving more of it as a therapy. Alternatively, the research may suggest that the IL1RN haplotypes are exerting their influence mainly by modulating other genes with key roles in the disease pathogenesis. It may be that they will emerge as targets that people hadnt even thought about in those diseases, he says.

Link:
New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health

Recommendation and review posted by Bethany Smith

INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ --Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.

"We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and dementia," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly.

The impact of this transaction will be reflected in Lilly's 2021 financial results according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly's 2021 financial guidance for research and development expense or non-GAAP earnings per share as a result of this transaction.

The Offer and the MergerThe tender offer for all of the outstanding shares of common stock of Prevail at a price of (i) $22.50 per share, net to the seller in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (a "CVR"), which CVR represents the contractual right to receive a contingent payment of up to $4.00 per share, net to the seller in cash, without interest and less any applicable tax withholding, which amount (or such lesser amount, as further described below) will become payable, if at all, if a specified milestone is achieved prior to December 1, 2028 (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern time, on January 21, 2021. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised Lilly that27,374,689 shares of Prevail common stock were validly tendered and not properly withdrawn in the Offer, representing approximately79.8 percent of the shares of Prevail common stock outstanding. All of the conditions to the Offer have been satisfied, and on January 22, 2021, Lilly and its wholly-owned subsidiary, Tyto Acquisition Corporation, accepted for payment, and will promptly pay for, all shares validly tendered and not properly withdrawn in the Offer.

Following completion of the Offer, Lilly completed the acquisition of Prevail through the merger of Tyto Acquisition Corporation with and into Prevail, without a vote of Prevail's stockholders pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Prevail surviving the merger as a wholly-owned subsidiary of Lilly. In connection with the merger, each share of common stock of Prevail not validly tendered in the Offer (other than (1) shares owned by Prevail (or held in Prevail's treasury) immediately prior to the effective time of the merger, (2) shares owned by Lilly, Tyto Acquisition Corporation or any other wholly owned subsidiary of Lilly immediately prior to the effective time of the merger or (3) shares held by any stockholder that was entitled to and has properly demanded statutory appraisal of such shares pursuant to, and who complied in all respects with, Section 262 of the Delaware General Corporation Law (the "DGCL") and who, as of the effective time of the merger, had neither effectively withdrawn nor lost its rights to such appraisal and payment under the DGCL with respect to such shares) has been cancelled and converted into the right to receive the same (i) $22.50 per share in cash, without interest and less applicable tax withholding, plus (ii) one CVR, as will be paid for all shares that were validly tendered and not properly withdrawn in the Offer. Prevail's common stock will be delisted from the NASDAQ Stock Market.

Under the terms of the agreement, Prevail stockholders were awarded one non-tradable CVR worth up to $4.00 per share in cash payable (subject to certain terms and conditions) upon the first regulatory approval for commercial sale of a Prevail product in one of the following countries: United States, Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028 (at which point the CVR will expire). There can be no assurance any payments will be made with respect to the CVR.

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com. C-LLY

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements about Lilly's acquisition of Prevail Therapeutics Inc. ("Prevail"), regarding contingent consideration amounts and terms, regarding Prevail's product candidates and ongoing preclinical development, regarding Lilly's development of a potential gene therapy program, and regarding Lilly's expected 2021 financial guidance and the impact of the acquisition on research and development expense and non-GAAP earnings per share. It reflects current beliefs and expectations; however, as with any such undertaking, there are substantial risks and uncertainties in integration of acquisitions, in drug research, development and commercialization, and in Lilly's evaluation of its estimated financial results for 2021 and the impact of the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that Lilly will be successful in building a gene therapy program, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2021 guidance or that Lilly can reliably predict the impact of the acquisition on its 2021 financial guidance and results. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission (the "SEC"). Except as required by law, Lilly does not undertake any duty to update forward-looking statements to reflect events after the date of this press release.

Refer to:

Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media)

Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)

View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-prevail-therapeutics-301213219.html

SOURCE Eli Lilly and Company

Here is the original post:
Lilly Completes Acquisition of Prevail Therapeutics - BioSpace

Recommendation and review posted by Bethany Smith

Databridgemarketresearch.com Present Cancer Gene Therapy Market Industry Trends and Forecast to 2027 new report to its research database. This report is always helpful to business or organization in every subject of trade for taking better decisions, solving the toughest business questions and minimizing the risk of failure. The studies of this report carefully analyzes the market status, growth rate, future trends, market drivers, opportunities, challenges, risks, entry barriers, sales channels, and distributors. The most advanced tools and techniques have been used to structure this Cancer Gene Therapy Market report such as SWOT analysis and Porters Five Forces Analysis. Moreover, different segments of the market taken into consideration in this market research report give better market insights with which reach to the success gets extended.

Cancer gene therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 6407.88 million by 2027 growing with the CAGR of 32.54% in the above-mentioned forecast period. The high success rate of cancer gene therapy along with clinical trial and preclinical trial is gaining popularity among the patient which is leading towards the market.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-gene-therapy-market&pm

The major players covered in the cancer gene therapy market report are Adaptimmune, GlaxoSmithKline plc, bluebird bio, Inc, Merck & Co., Inc., CELGENE CORPORATION, Anchiano Therapeutics, Achieve Life Sciences, Inc among other domestic and global players.

Competitive Landscape and Cancer Gene Therapy Market Share Analysis

Cancer gene therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to cancer gene therapy market.

Global Cancer Gene Therapy Market Scope and Market Size

Cancer gene therapy market is segmented on the basis of therapy and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Increase in funding of research and development in the activities of cancer gene therapy along with rise in prevalence of cancer is likely to accelerate the growth of the cancer gene therapy market in the forecast period of 2020-2027. On the other hand, the favourable government regulations for therapy is further going to boost various opportunities that will lead to the growth of the cancer gene therapy market in the above mentioned forecast period.

High cost involved in gene therapy along with unwanted immune responses wills likely to hamper the growth of the cancer gene therapy market in the above mentioned forecast period.

This cancer gene therapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market. To gain more info on Cancer gene therapy market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-gene-therapy-market&pm

Cancer Gene Therapy Market Country Level Analysis

Cancer gene therapy market is analysed and market size insights and trends are provided by country, therapy and end user as referenced above.

The countries covered in the cancer gene therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer gene therapy market due to the advanced healthcare infrastructure along with rise in R & D expenditure, while Asia-Pacific is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 due to the improving healthcare infrastructure and government initiatives.

The country section of the cancer gene therapy market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT GET FREE COVID-19 SAMPLE@ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-gene-therapy-market?pm

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Cancer gene therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer gene therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cancer gene therapy market. The data is available for historic period 2010 to 2018.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

Read more from the original source:
Cancer Gene Therapy Market : Future Prospects With Covid-19 Impact Analysis 2027 | Top Players- Adaptimmune, GlaxoSmithKline plc, bluebird bio, Inc -...

Recommendation and review posted by Bethany Smith

GlobalGene TherapyMarket Research Report and Forecast 2020-2025is the latest report byFior Marketswhich is the fastest growing market research company. The report provides a comprehensive scope of the market which includes future supply and demand scenarios, changing market trends, high growth opportunities, and in-depth analysis of the future market prospects. The report features real-time developments in the globalGene Therapymarket encompasses a highly structured and comprehensive outlook of the market. It shows market types and applications that are categorized as ideal market segments. The report covers the competitive data analysis of the emerging and prominent players of the market. Along with this, it provides comprehensive data analysis on the risk factors, challenges, and possible new market avenues.

The report has viewed the current top players and the forthcoming contenders. Business procedures of the vital participants and the new entering market ventures are concentrated in detail in this report. The report also encompasses SWOT investigation, income offer, and contact data. The report throws light on specific drivers, restraints, opportunities, challenges, and other determinants that tremendously favor and oppose normal growth in the globalGene Therapymarket. It also covers the product pricing factors, growth, emerging and dominant trends, overall market dynamics, and market size. The report includes a wide spectrum of the market to provide insightful data for the forecast period 2020-2025.

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376052/request-sample

The report gives the market segments that have been fragmented into sub-segments. The study gives a transparent view of the global market and includes a thorough competitive scenario and portfolio of the key players functioning in it. The report offers fundamental opinions regarding the market landscape, emerging and high-growth sections of the globalGene Therapymarket, high-growth regions, and market drivers, restraints, and also market chances. It targets estimating the current market size and growth potential of the global market across sections such as also applications and representatives.

Competitive Analysis:

Te report accurately profiles key vendors and players functioning in the globalGene Therapymarket, in terms of their ranking and core competencies, together with determining the competitive landscape. It also studies competitive developments such as partnerships and collaborations, mergers, and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the global market.

The top key players profiled in this report are:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics

Other Segment Analysis:

Segment classification of the market structure has been encouraged by our research experts to allow readers to comprehend the versatility of the market in terms of product and service variation. The market has been examined with vital market-specific developments across segment categories. Market segments such as type and application are also determined by quantitative and qualitative review. Type market size bifurcated into its product typeGermline Gene Therapy and Somatic Gene Therapyin terms of Volume (K Units) and Value (USD Million). Market segment by application, split into:Cardio Vascular Diseases, Infectious Diseases, Genetic Disorders, Neuro Disorders, Cancer, Others

Request forCustomization:https://www.fiormarkets.com/enquiry/request-customization/376052

Country-Wise Assessment:

The report presents an understanding of the regional, country, and even local developments. Overview of globalGene Therapy market dynamics such as industry outlook, value chain developments, SWOT and PESTEL assessment as well as Porters Five Point analysis. The report also encompasses crucial analytical reviews on key elements, trends, current, and future perspectives. By regional analysis, the report covers:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

See more here:
Global Gene Therapy Market Worth $38.41 Million by 2025- Exclusive Report by Fior Markets - PharmiWeb.com

Recommendation and review posted by Bethany Smith

LabCorps contract research organization business Covance has promoted Maryland Franklin, Ph.D., to vice president and head of its cell and gene therapy unit.

She moves up from being Covances site lead and executive director of scientific development at the Ann Arbor, Michigan, facility, which focuses on preclinical oncology.

Now, she steps up to run its cell and gene therapy business, a major element in any CRO's portfolio these days as more and more biopharmas look to tap the therapies for potentially curative treatments for a range of diseases.

It remains a tricky proposition to pull off, but cell and gene therapy are very much the current course for R&D across the life sciences as well as a major part of Covances business. Under her new role, Franklin will oversee these offerings.

These solutions aim to help sponsors reduce risk, transition programs within and between phases of development faster and create a more patient-centric experience, Covance said in a statement, as Franklin will also be tapped to further extend Covance by Labcorps industry leading position.

RELATED: Covance to 'transform' into a decentralized CRO

We are thrilled to welcome Dr. Franklin to Covance by Labcorp. Her experience and expertise will bring perspective and insight to cell and gene therapy at Covance, said Bill Hanlon, Ph.D., president of clinical, therapeutic and regulatory sciences for Covance.

Dr. Franklin joins us at a critical juncture in our ability to support sponsors needs throughout the drug development process. She will guide our highly experienced scientists across functional disciplines to seamlessly develop and commercialize a cell or gene therapy. With Dr. Franklins expertise, we hope to further grow and advance our cell and gene therapy programs.

Cell and gene therapy approaches continue to show great promise in treating a variety of diseases that range from extremely debilitating rare diseases to applications in oncology, added Franklin. With several approved advanced therapies to date and many, many more in development, Im excited to join Covance by Labcorp to and help sponsors in their mission to improve the lives of patients.

.

Link:
Covance boosts Franklin to lead its cell and gene therapy unit - FierceBiotech

Recommendation and review posted by Bethany Smith

Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Due to the high success rate during the preclinical and clinical trial, cancer gene therapy is gaining popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.

The global Cancer Gene Therapy market is expected to expand at a CAGR of +32% over the forecast period 2019-2025.

The report, titled Global Cancer Gene Therapy market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

Top Key Vendors in Market:

Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBiono GeneTech, and Altor Bioscience.

Get Sample Copy of this Report @ https://www.a2zmarketresearch.com/sample?reportId=53964

Cancer Gene Therapy market has been studied in terms of all parameters such as applications, types, products and many other. Each and every data leading to growth or fall of the respective segments have been explained. Entire supply chain with respect to market is studied in depth and is conveyed in the most comprehensive way possible. The reasons there is going to be an increasing trend to this market are studied and are elaborated. Driving forces, restraints and opportunities are given to help give a better picture of this market investment for the forecast period.

Different global regions such as North America, Latin America, Asia-Pacific, Europe, and India have been analyzed on the basis of the manufacturing base, productivity, and profit margin. This Cancer Gene Therapy market research report has been scrutinized on the basis of different practical oriented case studies from various industry experts and policymakers. It uses numerous graphical presentation techniques such as tables, charts, graphs, pictures and flowchart for easy and better understanding to the readers.

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cancer Gene Therapy market in the near future.

Get Discount on this Report @ https://www.a2zmarketresearch.com/discount?reportId=53964

Key questions answered in the report include:

Table of Content:

Global Cancer Gene Therapy Market Research Report 2019-2025

Chapter 1: Industry Overview

Chapter 2: Cancer Gene Therapy Market International and China Market Analysis

Chapter 3: Analysis of Revenue by Classifications

Chapter 4: Analysis of Revenue by Regions and Applications

Chapter 5: Analysis of Cancer Gene Therapy Market Revenue Market Status.

Chapter 6: Sales Price and Gross Margin Analysis

Continue for TOC..

For more Information:

https://www.a2zmarketresearch.com/enquiry?reportId=53964

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About a2zmarketresearch:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4147

sales@a2zmarketresearch.com

See the original post:
Explore why Cancer Gene Therapy Market is thriving by 2025 with top key players like Genelux Corporation, Cell Genesys, Advantagene, GenVec,...

Recommendation and review posted by Bethany Smith

New York, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Transient Protein Expression Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product Type ; Application ; End User, and Geography." - https://www.reportlinker.com/p06010110/?utm_source=GNW However, high cost of products are likely to pose a negative impact on the market growth.Transient protein expression procedure has been widely in use for animal and plant cells for the last three decades.However, in the recent years, significant evolution in proteomics has resulted in the development of recombinant proteins.

The effective results of transient protein expression in animals and plants have increased research and product development for human applications.Various companies, including biopharmaceuticals and contract research and development organizations have channelized their efforts toward the development of products based on transient protein expression.The adoption of transient protein expression allow companies to get various genes to develop recombinant proteins without delaying cell line generation.

Thus, the quick process of cell line development with required gene expression, companies are widely attracted towards uniform proteins that have drug-like properties, which allows production of vaccines and viral vectors. In addition, the transient protein expression process is widely being used in the production of monoclonal antibodies, modified human proteins, growth factors and cytokines, hormones, and blood products.The COVID19 pandemic has resulted in rise in the use of transient protein expression in vaccine development.Various researchers have started studying the novel coronavirus extensively, with the use of transient protein expression.

For instance, in MarchApril 2020, Absolute Antibody (UK) increased the production of multigram quantities of multiple anti-SARS-CoV-2 spike proteins to develop neutralizing antibodies. Similarly, the transient protein expression was widely used to produce a positive control protein in the development of in-vitro diagnostics kits.Product Type InsightsThe transient protein expression market by product type is segmented into instruments, reagents, vectors, and competent cells.In 2019, instruments segment held a largest market share in the transient protein expression market, by product type.

This segment is also expected to dominate the market in 2027 as they are the reducing human input is that it enables continuous cell maintenance and protein production. Moreover, the similar segment is anticipated to also witness the fastest growth rate during the forecast period.

Application InsightsBased on application, the global transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development.In 2019, the genomic research segment held the largest market share in the transient protein expression market.

This segment is also expected to dominate the market by 2027 as it increases DNA sequencing performance. Moreover, transient protein expression has helped in the study of all the genes of a person (the genome), including their interactions with each other as well as the environment.

End User InsightsIn terms of end user, the global transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations.In 2019, the pharmaceutical and biotechnology companies segment held the largest market share.

This segment is also expected to dominate the market during the forecast period as pharmaceutical and biotechnology firms are increasing their spending on research and R&D activities. Moreover, transient protein expression has helped the recent improvements in existing technologies and it is moving toward industrial production of plant-based vaccines, antibodies, and biopharmaceuticals.Major primary and secondary sources for transient protein expression included in the report are National Research Council Canada, UK BioIndustry Association, Australian Cluster Observatory and McKell Institute, UAE Federal Customs Authority, and Alpen Capitals report, among others.Read the full report: https://www.reportlinker.com/p06010110/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The global transient protein expression market is expected to reach US$ 983.10 million by 2027 from US$ 660.00 million in 2019 - GlobeNewswire

Recommendation and review posted by Bethany Smith

New York, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Increased investment in advanced technologies for treatment of genetic and chronic diseases is driving growth of the regenerative medicine market.Market Size USD 7.34 Billion in 2019, Market Growth - CAGR of 15.6%, Market TrendsApplications in COVID-19 vaccine.

The global regenerative medicine market is forecast to reach a market size of USD 23.57 Billion by 2027, and register a robustly incline revenue growth, according to a new report by Reports and Data. Primary factors driving demand for regenerative medicines are advancements in surgical technology and monitoring devices, and major increase in prevalence of complex and degenerative diseases. Upsurge in incidence of cancers has been resulting in increasing research into stem cell therapy. Growth in research and development activities in emerging countries and rising focus on stem cell research is resulting in significant growth in the global revenue of regenerative medicine market.

Stem cell technology is growing rapidly and continues to play a crucial role in regenerative medicine and the related field. This technology opens up the possibility of treating Parkinsons Disease, arthritis, and spinal cord injury. Increase in demand for stem cell technology is a major factor driving growth of the regenerative medicine market.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3735

Recent developments in regenerative medicine for 3D bioprinting, stem cell treatment for heart repair, and vision loss has created demand for additional investments in the R&D of the technology to help with other diseases.

The COVID-19 impact:

Demand for regenerative medicine has witnessed increased demand during the COVID-19 pandemic. Regenerative medicine helps in understanding a mechanism of infection and to develop ways to prevent the spread of the virus. It is also being used to create advanced treatments to treat persons infected by the COVID-19 virus. Private companies are also using it to develop an effective vaccine for COVID-19.

Regenerative Medicine Market Size, Share & Industry Demand By Product (Tissue-Engineered Products, Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies), By Application (Musculoskeletal Disorders, Oncology, Wound Care, By Material), and Region, Segment Forecast to 2027, To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/regenerative-medicine-market

Further key findings from the report suggest

List of Key Companies Identified in the Regenerative Medicine Market Report:

Order Now: https://www.reportsanddata.com/checkout-form/3735

For the purpose of this report, Reports and Data has segmented into the global regenerative medicine market on the basis of product, application, material, and region:

Browse similar research reports:Cell Therapy Market By Therapy Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Malignancies, Autoimmune Disorders, Musculoskeletal Disorders), By Cell Type, And By End User, Forecasts To 2027

Tissue Engineering Market Size, Growth & Analysis, By Material, By Application (Cancer, Urology, Neurology, Dental, Cell Banking & Cord Blood, Gynecology, Integumentary/Skin, Spine, Musculoskeletal, & Orthopedics, Vascular & Cardiology), And Region, Segment Forecasts To 2027

Gene Expression Market By Product And Services (Equipment, Consumables, And Services), By Capacity (Low- To Mid- Plex Gene Expression Analysis And High-Plex Gene Expression Analysis), By Application (Diagnostic, Drug Discovery, Research), And Segment Forecasts To 2027

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: sales@reportsanddata.com

Read full Press Release at:https://www.reportsanddata.com/press-release/global-regenerative-medicine-market

See the original post here:
Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism...

Recommendation and review posted by Bethany Smith

Databridgemarketresearch.com Present Cancer Gene Therapy Market Industry Trends and Forecast to 2027 new report to its research database. This analysis offers an examination of a range of segments that are relied upon to witness the quickest development amid the estimate forecast frame. The company profiles of all the key players and brands that are dominating the Cancer Gene Therapy Market with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. A complete discussion about numerous market related topics in this research report is sure to aid the client in studying the market on competitive landscape. This report also gives you an idea about consumers demands, preferences, and their altering likings about particular product.

Cancer gene therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 6407.88 million by 2027 growing with the CAGR of 32.54% in the above-mentioned forecast period. The high success rate of cancer gene therapy along with clinical trial and preclinical trial is gaining popularity among the patient which is leading towards the market.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-gene-therapy-market&pm

The major players covered in the cancer gene therapy market report are Adaptimmune, GlaxoSmithKline plc, bluebird bio, Inc, Merck & Co., Inc., CELGENE CORPORATION, Anchiano Therapeutics, Achieve Life Sciences, Inc among other domestic and global players.

Competitive Landscape and Cancer Gene Therapy Market Share Analysis

Cancer gene therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to cancer gene therapy market.

Global Cancer Gene Therapy Market Scope and Market Size

Cancer gene therapy market is segmented on the basis of therapy and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Increase in funding of research and development in the activities of cancer gene therapy along with rise in prevalence of cancer is likely to accelerate the growth of the cancer gene therapy market in the forecast period of 2020-2027. On the other hand, the favourable government regulations for therapy is further going to boost various opportunities that will lead to the growth of the cancer gene therapy market in the above mentioned forecast period.

High cost involved in gene therapy along with unwanted immune responses wills likely to hamper the growth of the cancer gene therapy market in the above mentioned forecast period.

This cancer gene therapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market. To gain more info on Cancer gene therapy market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-gene-therapy-market&pm

Cancer Gene Therapy Market Country Level Analysis

Cancer gene therapy market is analysed and market size insights and trends are provided by country, therapy and end user as referenced above.

The countries covered in the cancer gene therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer gene therapy market due to the advanced healthcare infrastructure along with rise in R & D expenditure, while Asia-Pacific is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 due to the improving healthcare infrastructure and government initiatives.

The country section of the cancer gene therapy market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT GET FREE COVID-19 SAMPLE@ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-gene-therapy-market?pm

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Cancer gene therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer gene therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cancer gene therapy market. The data is available for historic period 2010 to 2018.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

Excerpt from:
Cancer Gene Therapy Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 - The Courier

Recommendation and review posted by Bethany Smith

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has received both rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration (FDA) for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy.

There are no approved therapies for epilepsy caused by SLC13A5 that address the underlying cause of this disease, said RA Session II, President, Founder and CEO of Taysha. We are encouraged by the early evidence of TSHA-105s disease-modifying approach and believe these designations will help us potentially accelerate the development of this exciting program. We look forward to working with the FDA to make TSHA-105 available to patients as expeditiously as possible.

SLC13A5 is a form of infantile epilepsy caused by mutations in the SLC13A5 gene. The disorder is an autosomal recessive disorder, so two copies of the mutated gene must be inherited to affect an infant. This rare form of epilepsy manifests as developmental delay, and seizures beginning within the first few days of life.

We are pleased that the FDA recognizes TSHA-105s potential as an innovative therapeutic option for SLC13A5 deficiency, said Rachel Bailey, Ph.D., Assistant Professor in Pediatric Neurology at UT Southwestern. This disease is a debilitating form of genetic epilepsy in children that significantly impacts movement, motor control, cognition and quality of life, and there remains a need to alter the course of this disease early in life.

As a mother of two children with SLC13A5 deficiency, I have witnessed firsthand the devastating impact that numerous seizures and comorbidities accompanying the disease has on those affected by this disease, said Kim Nye, Founder of TESS Research Foundation. Tayshas commitment to developing a potentially life-changing gene therapy for SLC13A5 deficiency is greatly welcomed by our patient community.

The FDA grants rare pediatric disease designation for serious and life-threatening diseases that primarily affect children ages 18 years or younger and fewer than 200,000 people in the United States. The Rare Pediatric Disease Priority Review Voucher Program is intended to address the challenges that drug companies face when developing treatments for these unique patient populations. Under this program, companies are eligible to receive a priority review voucher following approval of a product with rare pediatric disease designation if the marketing application submitted for the product satisfies certain conditions, including approval prior to September 30, 2026 unless changed by legislation. If issued, a sponsor may redeem a priority review voucher for priority review of a subsequent marketing application for a different product candidate, or the priority review voucher could be sold or transferred to another sponsor.

Orphan drug designation is granted by the FDA Office of Orphan Products Development to investigational treatments that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the United States. The program was developed to encourage the development of medicines for rare diseases, and benefits include tax credits and application fee waivers designed to offset some development costs, as well as eligibility for market exclusivity for seven years post approval.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, intends, projects, and future or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates, including TSHA-105, to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential benefits of rare pediatric disease designation and orphan drug designation to our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on managements current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (SEC) filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which is available on the SECs website at http://www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Read the original post:
Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5...

Recommendation and review posted by Bethany Smith

New York, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Gene Therapy Market 2021-2025" - https://www.reportlinker.com/p05060878/?utm_source=GNW Our report on cancer gene therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the side effects of traditional cancer treatments, benefits associated with gene therapy for cancer treatment and the rising prevalence rate of cancer boosting the demand for cancer therapeutics. In addition, the side effects of traditional cancer treatments is anticipated to boost the growth of the market as well. The cancer gene therapy market analysis includes application segments and geographical landscapes.

The cancer gene therapy market is segmented as below: By Application Oncolytic virotherapy Gene transfer Gene-induced immunotherapy

By Geographical Landscapes North America Europe Asia ROW

This study identifies the rising partnerships and collaborations as one of the prime reasons driving the cancer gene therapy market growth during the next few years. Also, favorable government regulations for gene therapy programs and rapid growth potential in developing economies will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on cancer gene therapy market covers the following areas: Cancer gene therapy market sizing Cancer gene therapy market forecast Cancer gene therapy market industry analysis

Read the full report: https://www.reportlinker.com/p05060878/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
The Global Cancer Gene Therapy Market is expected to grow by $ 2.96 bn during 2021-2025 progressing at a CAGR of 20% during the forecast period -...

Recommendation and review posted by Bethany Smith

Gene Therapy Technologies Market Report recently published by Worldwide Market Reports company focuses mostly on required solutions to the users. The study includes analysis, forecast, and revenue from 2021 to 2026. The advancement rate is evaluated dependent on insightful examination that gives credible information on the worldwide market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of this market.

There is Continuous growth in the Gene Therapy Technologies Market in the last five years and also continued for the forecasted period. Gene Therapy Technologies industry report analyses the outline of the global market with respect to major regions and segmented by types and applications. This report covers top manufacturers, product scope, market overview, market opportunities, market risk, market driving force, technological advancement, distributors, traders, dealers, research findings.

RequestMore Detailed Information About Industry: Get Sample Report Click Here!

The top players covered in Gene Therapy Technologies Market are: Bluebird bio, Adaptimmune, GlaxoSmithKline, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology

The point-to-point elucidation of the markets assembling system, the usage of advancement, conclusions of the world market players, dealers and suppliers order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Gene Therapy Technologies market.

The data always remains relevant to the market and consists of market dynamics, prospects, starts, market dynamics, and even the Global market volumes into account. It filled with data and deep analysis on market value, environmental analysis, Gene Therapy Technologies advanced techniques, latest developments, Gene Therapy Technologies business strategies, and current trends. Hence, it becomes a valuable asset to both manufacturers and investors of the industry.

Points Covered of this Gene Therapy Technologies Market report are:

The international Gene Therapy Technologies market has been characterized by several primary factors, with each factor tends to play a crucial role in the boom of the market. The growth in the products has doubled with the smoother availability of the customer base that has been helping the company flourishing globally. On the other hand, the presence of a dynamic supply chain has helped the company to grow exponentially.

The analysis and forecast of the global market of Gene Therapy Technologies have no longer been, specifically, analyzed that are not only on a global foundation but additionally on a neighborhood foundation. When a better look taken at the areas, the market has concentrated, and the file interior the important makes a strong point of Europe, Middle East & Africa, Asia Pacific, Latin America, and North America. These areas have studied regarding the hooked-up traits and the diverse possibilities in addition to the outlook that allows inside the benefitting of the market ultimately.

Request Discount for this Research:(Click Here!)

Research Methodology:

The Gene Therapy Technologies market report has been prepared after thorough market research being conducted. It has been prepared as per Porters Five Force Model. In terms of timeline, the market takes the period between 2021-2026 into account for assessment. Apart from this, a comprehensive SWOT analysis has been provided for swift business decision making.

Enumerating some of the fundamental parameters encompassed in the report:

Global Gene Therapy Technologies Market Report includes Detailed TOC points:

Customization Service of the Report: (Place Query: Click Here!)

Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you get a report that suits your necessities.

Contact Us:Mr. ShahWorldwide Market Reports,Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737Email: sales@worldwidemarketreports.com

Read the original here:
Gene Therapy Technologies Market Estimated to Experience a Hike in Growth by 2021 2026: Bluebird bio, Adaptimmune, GlaxoSmithKline - KSU | The...

Recommendation and review posted by Bethany Smith

Drugs that target the cancer-promoting proteins MDM2 and BET have been tried in acute myeloid leukemia (AML) and haven't been all that effective on their own. But what if they were combined?

Researchers at the Sanford Burnham Prebys Medical Discovery Institute and the University of Glasgow have early evidence a combination strategy may, in fact, work in AML.

Combining MDM2 and BET inhibitors improved the killing of AML cell lines in lab studies and was more effective than solo treatment in eradicating the cancer in mouse models, the researchers reported in the journal Nature Communications. The combination seems to work by activating the tumor-suppressing protein p53, they reported.

The results were surprising because previous research had shown that each drug on its own had modest benefit against AML, said senior author Peter Adams, Ph.D., a professor at Sanford Burnham Prebys, in a statement. The new research provides scientific rationale to advance clinical studies of the drug combination in patients with AML.

The gene TP53 produces the protein p53, a known tumor suppressor. TP53 is frequently mutated across a range of cancers, which is why targeting the gene is a popular pursuit in oncology research.

Until now, the popular thinking was that MDM2 inhibitors activate p53. BET inhibitors, on the other hand, suppress leukemia-associated genes but dont affect p53, researchers believed.

Adams and his team tested MDM2 and BET inhibitors in AML cell lines and samples from patients. They were surprised to discover that BET inhibitors actually do activate p53by suppressing another protein called BRD4. Combining MDM2 and BET inhibition produces a 'double whammy' effect that fully unleashes the anti-cancer activity of p53, Adams said.

RELATED: How novel combos could overcome resistance to targeted drugs in leukemia, solid tumors and more

The Sanford Burnham Prebys-led team went on to test the combination in two mouse models of AML. In both cases, inhibiting BET and MDM2 together outperformed either mechanism on its own in eradicating the cancer and extending survival, the researchers reported.

The biopharma industry continues to show an interest in both BET and MDM2 inhibitors, though development efforts have run into some obstacles.

In 2019, Roche dropped a phase 1 BET inhibitor from its pipeline. And last April, the Swiss pharma giant stopped testing MDM2 inhibitor idasanutlin in a phase 3 AML trial after a combination of the drug with cytarabine proved disappointing. Early trials of idasanutlin in combination with Roches AML drug Venclexta are underway.

Meanwhile, other early-stage BET and MDM2 inhibitors have driven some deal-making in biopharma. In 2018, Aptose Biosciences teamed up with Ohm Oncology to advance a BET inhibitor in hematologic cancers. And last September, Rain Therapeutics licensed an MDM2-targeted drug from Daiichi Sankyo and raised $63 million to take it into pivotal trials in differentiated or dedifferentiated liposarcoma.

The Sanford Burnham Prebys and University of Glasgow researchers noted in their study that the heterogeneity of AML makes it a particularly difficult disease to address with targeted treatments. While many different genes can be mutated to drive the disease, no single mutation is dominant in a majority of patients.

But 90% of AML tumors have TP53, suggesting that human AML subtypes employ alternative mechanisms to inactivate the p53 pathway.

Go here to read the rest:
Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatment - FierceBiotech

Recommendation and review posted by Bethany Smith

Rising Demand for Gene Therapy Market 2021

Gene Therapy Market analysis on global market is a thorough study that offers a select combination of skillful market realities. The study shows changing market trends as well as the size of individual segments in this market. This report mentions various top players involved in this market. Analysis of the Global Gene Therapy Market begins with a market-based outline and underlines the current information on the global market, complemented by data on the current situation.

Global Gene Therapy Market report is a comprehensive study of the global market and has been recently added by Market Research Inc to its extensive database. Augmented demand for the global market has been increased in the last few years. This informative research report has been scrutinized by using primary and secondary research. The Global Gene Therapy Market is a valuable source of reliable data including data of the current market.

Ask for Sample Copy of This Report:

https://www.marketresearchinc.com/request-sample.php?id=23888

Top Key Players Profiled in This Report

Novartis AG, Gilead Sciences, Inc., UniQure N.V., Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline PLC, Celgene Corporation, Shire PLC,

The key questions answered in the report:

Across the globe, different regions such as North America, Latin America, Asia-Pacific, Europe, and Africa have been examined on the basis of productivity and manufacturing base. Researchers of this report throw light on different terminologies of the Global Gene Therapy Market.

This research report represents a 360-degree overview of the competitive landscape of the Global Gene Therapy Market. Furthermore, it offers massive data relating to the recent trends, technological advancements, tools, and methodologies. The research report analyzes the Global Gene Therapy Market in a detailed and concise manner for better insights into the businesses.

The research study has taken the help of graphical presentation techniques such as info graphics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Gene Therapy Market.

The detailed elaboration of the Global Gene Therapy Market has been provided by applying industry analysis techniques such as SWOT and Porters five-technique. Collectively, this research report offers a reliable evaluation of the global market to present the overall framework of businesses.

Get Discount on This Report:

https://www.marketresearchinc.com/ask-for-discount.php?id=23888

Table of Contents:

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

If You Have Any Query, Ask Our Experts:

https://www.marketresearchinc.com/enquiry-before-buying.php?id=23888

About Us

Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact Us

Market Research Inc

Kevin

51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us:+1 (628) 225-1818

Write Us@sales@marketresearchinc.com

See the article here:
Big Boom in Gene Therapy Market Detailed Analysis of Current and Future Industry Figures till 2028 |Novartis AG, Gilead Sciences, Inc., UniQure N.V.,...

Recommendation and review posted by Bethany Smith

Reuters | Published: January 21, 2021 10:37:09 | Updated: January 21, 2021 14:27:09

Scientists in Beijing have developed a new gene therapy which can reverse some of the effects of ageing in mice and extend their lifespans, findings which may one day contribute to similar treatment for humans.

The method, detailed in a paper in the Science Translational Medicine journal earlier this month, involves inactivating a gene called kat7 which the scientists found to be a key contributor to cellular ageing.

The specific therapy they used and the results were a world first, said co-supervisor of the project Professor Qu Jing, 40, a specialist in ageing and regenerative medicine from the Institute of Zoology at the Chinese Academy of Sciences (CAS).

These mice show after 6-8 months overall improved appearance and grip strength and most importantly they have extended lifespan for about 25%, Qu said.

The team of biologists from different CAS departments used the CRISPR/Cas9 method to screen thousands of genes for those which were particularly strong drivers of cellular senescence, the term used to describe cellular ageing.

They identified 100 genes out of around 10,000, and kat7 was the most efficient at contributing to senescence in cells, Qu said.

Kat7 is one of tens of thousands of genes found in the cells of mammals. The researchers inactivated it in the livers of the mice using a method called a lentiviral vector.

n liver cell and the mouse liver cell and for all of these cells we didnt see any detectable cellular toxicity. And for the mice, we also didnt see any side effect yet.

Despite this, the method is a long way from being ready for human trials, Qu said.

Its still definitely necessary to test the function of kat7 in other cell types of humans and other organs of mice and in the other pre-clinical animals before we use the strategy for human ageing or other health conditions, she said.

Qu said she hopes to be able to test the method on primates next, but it would require a lot of funding and much more research first.

In the end, we hope that we can find a way to delay ageing even by a very minor percentage...in the future.

See the article here:
Gene therapy developed to delay ageing - The Financial Express BD

Recommendation and review posted by Bethany Smith

January is National Thyroid Awareness Month, a time dedicated to promoting the prevention, treatment, and cure of thyroid-related illnesses. Thyroid disease is more common than you may thinkan estimated 20 million Americans have some form of thyroid disease and up to 60 percent of them dont know they have it, according to the Cleveland Clinic. Women are also at higher risk and are five to eight times more likely to develop thyroid disease than men.

Youre probably wondering what is the thyroid and why is thyroid disease so common? Small but mighty, the thyroid is a butterfly-shaped gland that sits at the base of your neck, says the Centers for Disease Control and Prevention (CDC). This gland controls the rate at which every cell, tissue, and organ in your body functions, including the brain, heart, and digestive tract. The thyroid is the master controller of metabolic function throughout the body, Dr. Ryan M. Green, DO, MS, the Medical Director of Preg Appetit! and Principal Medical Advisor at Monarch Athletic Club in West Hollywood tells The Beet. This is because the thyroid produces the hormones T3 and T4, which regulates your metabolism a chemical activity of cells converting nutrients into energy.

There are two main types of thyroid disorders most common in the United States:Hypothyroidism is when the thyroid gland doesnt make enough hormone and hyperthyroidism is when the thyroid gland makes too much hormone, says the Cleveland Clinic. Imbalance in either direction regarding thyroid function can have a major impact on how someone lives day-to-day, explains Dr. Green. As seen with most non-infectious illnesses nowadays, thyroid diseases are generally provoked by increased environmental toxins in the air, water, and food. Another popular cause entails nutritional deficiencies or imbalances, which means youre probably not getting the right nutrients to support your thyroid, says Dr. Green. Unfortunately, many of the nutrients that are essential for proper thyroid function are not made by the body and therefore need to be consumed in our diet, Ashley Shaw, MS, RDN, a registered dietician at Preg Appetit! tells The Beet. Adequate levels of these nutrients allow the thyroid to produce and secrete hormones that are invaluable to normal body processes, including but not limited to, rate of metabolism, bone development, muscle growth and contraction, speed of heartbeat, and body temperature regulation. Below, we have listed five nutrient-rich foods that can optimize thyroid function and help prevent disease.

If youre a big fan of sushi, youre surely going to love this one. Seaweed, aka sushi wrapper, is a form of edible algae that grows in the sea. It is naturally full of iodine with some varieties containing up to 2000% of the daily value. Iodine is a nutrient used by the thyroid gland, essential for the development of thyroid hormones that have many functions, says Shaw. It is not something our bodies make on their own, so we have to get it from foods or supplements. Its important to keep the right balance of iodine in your diet, according to a 2019 study. Researchers found that while some people can tolerate high amounts of iodine, it may lead to hyperthyroidism or thyroid autoimmunity. Be aware of your iodine intake and incorporate a variety of seaweed, such as hijiki, nori, and Irish sea moss in your diet.

Brazil nuts are one of the richest sources of selenium, a key nutrient in preventing thyroid disease. The recommended daily intake of selenium is 55 mcg for adults and brazil nuts, on average, contain 96 mcg per nut. Since the 1990s, selenium has been widely researched as an enzyme that activates the thyroid hormone, according to a 2020 study. Data from previous studies have shown that a low selenium status is linked to autoimmune thyroiditis and Graves disease an autoimmune disorder that causes hyperthyroidism. Start incorporating more selenium in your diet with brazil nuts but beware of consuming them in large numbers, says the National Institutes of Health (NIH). Taking more than 400 mcg of selenium per day (for adults) can lead to serious health implications like myocardial infarction, kidney failure, and more. So approach with caution its all about keeping the right balance!

Believe it or not, the most nutritious part of a pumpkin is the pumpkin seeds as they are filled with vitamins and minerals while being low in calories. Pumpkin seeds are high in zinc, which are especially important for the thyroid hormones T3 and T4, explains Shaw. A 2019 study found that zinc is a crucial part of the enzyme deiodinase which converts T4 into T3. These hormones play a significant role in homeostasis by facilitating the metabolism of blood sugar, responding to changes in energy intake, and controlling our bodys process of heat production. In other words, pumpkin seeds can do wonders for your thyroid. Add them to your salads, oatmeal, cereal, soup, and favorite dessert for a hearty and thyroid-boosting meal.

Weve surely raved about the powerful benefits of berries before in optimizing brain health, PMS symptoms, and PCOS. Its because berries are high in antioxidants that can neutralize harmful free radicals, which can cause inflammation and lead to negative health implications. Theyre also great for the thyroid as they have a low-glycemic index, considering too much sugar can create hormone imbalances and thyroid flares, according to a 2018 study. Researchers examined a case study and found that sugar substitutes can provoke the development of Hashimotos disease, leading to the failure of the thyroid gland. Berries are a great way to incorporate something sweet into your diet without compromising your thyroid health. Use them in smoothies, parfaits, and as a no-guilt, nutritious dessert.

A high fiber diet is not only beneficial for your heart and brain but also just as influential for your thyroid. Complex carbohydrates are full of fiber and also low-glycemic, which means they do not impact your blood sugar levels. Dietary fiber can help ease some of the symptoms associated with thyroid diseases, such as poor digestion and constipation, according to Harvard Health. It also prevents type 2 diabetes, weight gain, insulin resistance, and other health conditions that are associated with the greater risk of thyroid disease. Make sure to incorporate complex carbohydrates like brown rice, quinoa, and kidney beans in your diet to ensure a good supply of dietary fiber. However, do proceed with caution if youre on medication for your thyroid disorder as fiber can affect medication absorption, says Harvard Health.

Read more here:
The 5 Best Nutrient-Rich Foods to Improve Thyroid Function - The Beet

Recommendation and review posted by Bethany Smith

Medicare typically covers the cost of thyroid tests if a doctor deems them necessary. The diagnostic tools allow the healthcare provider to understand if someone has problems with their thyroid gland.

The thyroid gland, located in the neck, produces hormones that regulate metabolism. If an individual has a thyroid condition, they may experience weight control issues or cardiovascular complications.

This article explores thyroid dysfunction and discusses how Medicare covers thyroid and other blood tests. It also looks at treatments and therapies for thyroid dysfunction and examines costs.

We may use a few terms in this piece that can be helpful to understand when selecting the best insurance plan:

Thyroid dysfunction happens when the thyroid gland either makes too much or too little thyroid hormone.

The thyroid gland has two lobes on either side of the windpipe below the voice box or larynx. This endocrine gland makes two thyroid hormones, T3 and T4, which are chemical messengers controlling metabolism, growth, and mood.

If the thyroid gland does not make enough hormones for the body, this leads to hypothyroidism or an underactive thyroid. If the thyroid produces too much hormone, the individual experiences hyperthyroidism or overactive thyroid.

In hypothyroidism, symptoms include:

With hyperthyroidism, symptoms relate to increased metabolic rate and include:

Both forms of thyroid dysfunction affect the body in various ways and can lead to a range of symptoms. However, people with minor thyroid dysfunction may not experience any symptoms.

Learn more about common thyroid disorders here.

Different parts of Medicare cover the costs of thyroid tests and treatment.

Original Medicare is Part A, which is hospital insurance, and Part B, which provides medical insurance.

Medicare Part A covers the cost of inpatient stays in a hospital, clinic, or other nursing facilities. Medicare Part B covers medically necessary services in an outpatient setting, doctors visits, and prevention services, including diagnostic and blood tests.

Generally, Medicare covers thyroid testing under Part B, as long as a doctor has ordered the test to diagnose or treat a medical condition.

However, Part A covers the cost if a person is in a hospital or nursing facility, and a doctor orders a thyroid test during their inpatient stay. Medicare Part A also covers the cost if the doctor recommends surgical removal of the thyroid gland.

Learn more about the removal of the thyroid gland here.

People who qualify for Medicare can choose to get coverage through original Medicare (Parts A and B) or a through a Medicare Advantage plan.

While Medicare Advantage plans offer the same basic coverage as original Medicare, private insurance companies offer the plans, which means they may offer additional benefits, such as dental, vision, and hearing care. Many Advantage plans also provide Medicare Part D prescription drug coverage.

Learn more about choosing a Medicare Advantage plan here.

Medicare Part D is prescription drug coverage available to a person enrolled in original Medicare. Private insurance companies offer these plans.

If a doctor prescribes medication because a person has a mild thyroid condition, Medicare Part D covers the cost. People should check their plans list of drugs, called a formulary, to confirm coverage of thyroid medications.

Learn more about Medicare Part D here.

The various treatments and therapies for thyroid dysfunction depend on the severity of a persons condition. Medication is generally the first line of treatment.

Treatment usually includes synthetic thyroxine, which replaces the T4 hormone. The dosage depends on the levels of thyroid-stimulating hormone (TSH) in a persons blood.

Doctors use blood tests to monitor hormone levels and then adjust the dose of thyroxine as necessary.

Doctors may also recommend a dietary plan that improves iodine intake, including certain vegetables and soy products. Iodine is essential to healthy thyroid function.

Learn more about TSH tests here.

Doctors prescribe medications that either treat the symptoms of hyperthyroidism or address hormone production. Medications may include:

If the above treatments do not work or are not possible, surgery to remove the thyroid gland could be an option.

Learn about an overactive thyroid and Graves disease.

The cost of a thyroid blood test varies according to the laboratory and the location. Medicare covers most clinical diagnostic tests, including thyroid tests, but a person will generally have some costs, as shown below.

If a doctor orders a thyroid test while a person is an inpatient, Medicare Part A covers the cost after a person has met their deductible. The Part A deductible is $1,484 in 2021 for each benefit period. A benefit period starts as someone enters the hospital and continues for 60 days.

Medicare Part B covers the total cost for thyroid tests. However, a person must meet the annual deductible of $203. Other costs include the basic Part B monthly premium, which is $148.50 in 2021.

Costs for Advantage plans differ. In addition to paying the standard Part B premium, a person enrolled in an Advantage plan will pay the plan premium. In 2020, Advantage plan premiums averaged $25 per month.

Learn about the costs of Medicare in 2021.

Most people generally have zero costs for Medicare-covered clinical diagnostic tests, including thyroid tests. However, if a person needs help to cover the costs of thyroid treatment, they may find assistance from Medigap or Medicaid.

A Medigap plan helps a person enrolled in Medicare pay out-of-pocket costs such as copays, deductibles, and coinsurance that Medicare does not cover. Private insurance companies offer 10 Medigap plans with different levels of cover.

Costs vary by location and plan and can range from $64 to $500 per month.

Learn more about Medigap here.

Medicaid helps low-income, low resource households to access healthcare services. The government funds this program, and individual states set the eligibility criteria for income and assets.

Learn more about Medicaid here.

Original Medicare (Part A and Part B) and Medicare Advantage plans offer the same level of coverage for thyroid tests. Medicare Part B covers the cost of a blood test done as an outpatient, while MEdicare Part A covers the costs of a thyroid blood test done as part of an inpatient hospital stay.

Both Medicare Part D and Medicare Advantage plans cover the cost of thyroid medication. Medicare Part A also covers the cost of surgery if a doctor deems it necessary to remove the thyroid gland.

The thyroid gland is a small hormone-producing gland in the neck. People can experience problems if they produce too much or too little thyroid hormones that control metabolism and growth.

The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.

Follow this link:
Medicare and thyroid tests: Coverage, options, therapies, and costs - Medical News Today

Recommendation and review posted by Bethany Smith

An NHS trust has been allowed to appeal against a high court decision that barred it from referring under-16s for puberty-blocking treatment.

The court ruled that children considering gender reassignment were unlikely to be able to give informed consent. Now the Tavistock and Portman NHS trust, which runs the UKs main gender identity development service for children, has been granted permission to appeal, alongside University College Hospitals NHS foundation trust and Leeds Teaching Hospitals NHS trust.

In a statement, a spokesperson for the Tavistock, which leads the national Gender Identity and Development Service (Gids), said it welcomed the courts decision. Our priority is to work together with our partners to support our patients and their families while legal proceedings are ongoing, the spokesperson said.

At the start of December last year the London clinic lost a case brought by Keira Bell, a 23-year-old woman who began taking puberty blockers when she was 16 before detransitioning, and the unnamed mother of a 15-year-old autistic girl who is on the waiting list for treatment.

In their decision, Dame Victoria Sharp, president of the Queens bench division, Lord Justice Lewis and Mrs Justice Lieven, ruled that it unlikely that children under the age of 16 who were considering gender reassignment were mature enough to give informed consent to be prescribed puberty-blocking drugs.

In addition the judges ruled that even in cases involving teenagers under 18 doctors may need to consult the courts for authorisation for medical intervention. They added: It is doubtful that a child aged 14 or 15 could understand and weigh the long-term risks and consequences of the administration of puberty blockers.

At the time of the ruling an NHS spokesperson said the Tavistock had immediately suspended new referrals for puberty blockers and cross-sex hormones for the under-16s, which would henceforth only be permitted where specifically authorised by a court.

Susie Green, CEO of Mermaids, a charity providing support to transgender or non-gender-conforming children, said the initial ruling forced transgender young people to go to court to get basic healthcare.

Whatever our beliefs, most of us can agree that it is the young people themselves, together with their parents and their doctor, who best understand their needs, she said.

We are pleased to see that this ruling will now be challenged for the sake of every child who deserves the chance to live a happy life and be true to themselves.

In September last year the NHS launched an independent review into the future of gender identity services for children and young people to examine the use of puberty blockers and cross-sex hormone drugs as well as looking at how care could be improved.

The NHS service at Tavistock, to which those under the age of 18 with concerns about their gender are referred for treatment, has had a surge in demand from 77 in 2009 to 2,590 in 2018-19.

An inspection of the Tavistock and Portman NHS foundation trust gender identity services for children and young people by The Care Quality Commission due to report on Wednesday is expected to include feedback from people using the service, parents, relatives, carers and staff.

Link:
High court grants leave to appeal to UK gender identity service - The Guardian

Recommendation and review posted by Bethany Smith

If she found the right guy, Kari Arenberg could see herself having kids. But her work was never conducive to dating, let alone to freezing her eggs in hopes of leaving her options open. The 31-year-old event producer traveled constantly between New York City and Los Angeles, with long days lifting heavy boxes and running around venues.

Then, in 2020, Arenberg was furloughed, and the egg-freezing process became, for the first time in her life, logistically possible. She moved in with her family in Chicago and visited a clinic. Soon she was giving herself as many as three shots a day to stimulate her ovaries, and visiting the clinic every few days for bloodwork and an ultrasound to determine when the eggs would be ready for retrieval. She was able to freeze 21 eggs, a feat that likely would have been impossible if she had had to give herself shots while stuffed into airplane bathrooms or trying to schedule visits to the clinic around the national events, like Comic Con, that she produces. I love my work and want to prioritize it, Arenberg says. So its ironic that my career also kept me from doing this earlier.

When the coronavirus pandemic hit, fertility clinics braced themselves for a downturn. People have been avoiding the doctors office since the spring, first because they feared exposure to the virus and later because many people who have been laid off or furloughed cannot afford the medical bills. Fertility treatments are expensive, and the cost of egg freezing ranges from $6,000 to $20,000. (Arenbergs was $12,000an especially daunting cost after losing work.)

But clinics across the country are reporting an uptick in women freezing their eggs during the pandemic. Though no organization in the U.S. collects national data, 54 clinics across major American cities including Denver, Atlanta and Seattle told TIME that the number of women freezing their eggs has increased year-over-yearan impressive stat considering most of those clinics were forced to shut down and suspend fertility treatments in the early months of the pandemic. An additional five clinics reported the same number of egg freezing cycles in 2020 as in 2019 despite being closed anywhere from one to three months in 2020. Only two clinics told TIME they had seen a decrease in the number of women freezing their eggs since 2019. We didnt know what to expect, says Colleen Wagner Coughlin, the founder of OVA Egg Freezing Center in Chicago. If anything we expected a downturn. But weve seen a huge increaseseveral hundred more new patients [in 2020].

At some clinics, the changes have been robust. When TIME collected data in November, Shady Grove Fertility, which runs 36 clinics across the Eastern seaboard, had seen a 50% increase in women freezing their eggs since 2019. Doctors at NYU Langone saw a 41% year-over-year increase in women fertilizing their eggs. And Seattle Reproductive Medicine had conducted 289 egg-freezing cycles in 2020, compared with 242 in 2019, a nearly 20% jump.

Unable to see friends in person during the pandemic, Kari Arenberg, bottom right, relieved her nerves about self-administering hormone injections by sharing the process with friends over video chat The hormone shots cause a lot of bloating and cramping and emotions, says Arenberg. Its not exactly conducive to getting work done. It literally feels like youre carrying around a sack of eggs."

Courtesy of Kari Arenberg.

Sharon Covington, a therapist who provides counseling services at Shady Grove Fertility Clinic, is busier than ever offering mental health support to women considering fertility treatments, including egg freezing. She says the women she sees are freezing their eggs because of the pandemic, not in spite of it. Women who normally travel for work, like Arenberg, are grounded. Those with busy social lives are alone at home. Their schedules are open. But that time in isolation has also afforded space for reflection. Everybody had to take a hard stop in their lives, Covington says. And I think what happened with that is that it gave people the time and the space to kind of reassess their priorities and the directions that theyre taking in their life.

Many single people feel as if theyve fallen a year behind on their life plans. Dating was almost impossible at the beginning of the pandemic. Even now, near-strangers must negotiate a difficult social dance with one another when they agree to meet up for a distanced drinkwhen can they hug, kiss or even just go indoors together? When will they feel safe with one another? I actually went on a few dates, says Arenberg, but sitting outside shivering in Chicago in the winter is not conducive to finding someone.

Read More: The Coronavirus Is Changing How We Date. Experts Think the Shifts May Be Permanent

Arenberg first heard about egg freezing when the winner of the Bachelors 2015 season, Whitney Bischoff Angel, revealed that she froze her eggs. Egg freezing has steadily grown more popular in the years since the American Society of Reproductive Medicine (ASRM) removed the experimental label from the procedure in 2012. Many women were already freezing their eggs for medical reasons, either because they were going through a medical procedure like chemotherapy that could reduce their fertility or had a medical condition like endometriosis that could negatively impact ability to conceive. But with the change in labeling came the rise of what doctors call social egg freezingwomen who freeze their eggs simply because they arent ready to have a child yet. In 2009, just 475 women froze their eggs, according to the Society for Assisted Reproductive Technology. By 2018, 13,275 women did so, an increase of 2,695%.

The spike comes thanks in part to celebrities like Chrissy Teigen, Michaela Coel and Emma Roberts sharing their own egg-freezing stories. Kourtney Kardashian went so far as to film her egg freezing preparation on Keeping Up With the Kardashians, and Amy Schumer shared pictures of her bloated and bruised stomach as she took the shots this summer to freeze her eggs as part of her IVF process. Theyve demystified a process that was little known just a few years ago, including, in Schumers case, the most uncomfortable aspects.

Ren Hurtado, a 28-year-old in Scottsdale, Ariz., knew that she might have to stay home in the weeks before her egg retrieval in case she suffered side effects like cramping or headaches, and believed the pandemic would be the ideal time to nurse those pains without missing meetups with friends. On day five of injections, I couldnt even walk. I only felt good if I was lying flat on my bed, she says. She had to take several days off from her job at WeWork while she recovered. In an alternate world, I was supposed to be in Miami for a bachelorette party that week. Thank God I did this during COVID so I didnt have to see anyone or go anywhere because I was in so much pain.

Ren Hurtado, 28, took a selfie before a doctor retrieved her eggs at a clinic in Arizona

Courtesy of Ren Hurtado.

Hurtados offered egg freezing as part of the companys benefits package, a perk thats become increasingly popular among startups as a means of attracting women workers (or, in critics eyes, pressuring workers to prioritize work over family). But the trendiness of egg freezing in Silicon Valley may be reaching its peak. Some doctors have cast doubt as to whether companies will continue to offer this costly benefit when many organizations are choosing between cutbacks and layoffs. Wagner Coughlin, the founder of OVA in Chicago, said that her organization is already looking into a new payment structure in anticipation of companies dropping the benefit.

Michael Jacobs, a doctor at the IVF Center of Miami, believes that moment has already arrived. He was one of the few doctors who told TIME his clinic was seeing a downturn in egg-freezing rates. In cities like New York and Los Angeles, maybe there are more people who can afford the cost of egg freezing right now, he says. But I think a lot of people here are just worried about paying their bills.

The high price of egg freezing has long meant only a specific subset of patientsmostly upper class, and mostly whitepursue the process: a study of nearly 30,000 egg retrievals by ASRM found that just 4.5% of the women who underwent the procedure described themselves as Hispanic and 7% identified as Black.

Read More: Women Are Deciding Not to Have Babies Because of the Pandemic. Why Thats Bad for All of Us.

Pavna Brahma, a doctor at the Shady Grove clinic in Atlanta, theorizes that this may be the boom period before a bust. People are coming in who are worried about losing their job or their coverage or their insurance, Brahma says. They want to take advantage of the moment when they know they have coverage and economic stability in their job.

She stresses to her patients that waiting until they receive the vaccine to freeze their eggs is a viable option: Two to six months rarely makes a huge change in their fertility. I dont want women to feel pressured by the pandemic.

Bryn Woznicki, who lives in Los Angeles, decided to dedicate the money she had saved for a move to New York City to freezing her eggs last year

Courtesy of Bryn Woznicki.

Still, pandemic or not, time remains a key driver in womens family-planning decisions. As a general rule, the younger you are, the more eggs you have, and the more likely an egg-freezing process will be successful. Many women fear the benchmark of 35 years old. Loss of eggs and risks to pregnancy happen gradually over time, not all at once, but 35 is when doctors begin calling pregnancies geriatric to reflect increased risks. Its also the age at which fertility doctors will advise freezing more eggs, often through several procedures to harvest as many eggs as possible and improve the chances that one can be fertilized later.

Bryn Woznicki, a 33-year-old filmmaker who lives in Los Angeles, has always known she wants to be a mother, but every year, she says, its a ticking time bomb working against your biological clock. When filming work dried up last spring and dating became more difficult, she took stock of what turning 34 during a pandemic could mean. Say I met someone today, she says. Say I really liked them and we got married. By the time I did that and enjoyed my partner and we decided to take on this huge responsibility of having kids, thats another few years down the line.

With her work and social life on pause, she decided to divert some of her savings towards a potential future family. I had some money saved to try to move to New York this fall and then, you know, COVID happened, she says. Meanwhile I was feeling the pressure from my biology telling me that time was running out, and I was like this is the one thing I can control in an unpredictable year.

For Arenberg, being able to freeze her eggs was a silver lining of the pandemic. As unfortunate as it is that Im technically unemployed, this really gave me the mental capacity to look ahead for the first time, she says. I dont know if I want kids, but maybe if I meet the right person some day, this just provided a nice comfort level where I can make some decisions about dating and kids and work when things get back to normal.

For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Write to Eliana Dockterman at eliana.dockterman@time.com.

Original post:
Data Show More Women Are Freezing Their Eggs During the Pandemic, Defying Doctors Expectations - TIME

Recommendation and review posted by Bethany Smith

Keira Bell brought legal action against the Tavistock and Portman NHS Trust. (YouTube/Sky News)

The NHS has been granted permission to appeal a High Court ruling that said transgender under-16s cannot give informed consent to puberty blockers.

The Tavistock and Portman NHS Trust, which runs GIDS, the only gender clinic for trans youth in England and Wales, said it would appeal the ruling when it lost the judicial review in December 2020.

The Tavistocks appeal has now been granted, it was confirmed Monday (18 January), and will be heard before 22 March, 2022. A spokesperson for the Trust said they welcome the courts decision to allow their appeal against the ruling.

Our priority is to work together with our partners to support our patients and their families while legal proceedings are ongoing, the spokesperson said. The judges ruled in December that the judgment will not be implemented until the outcome of the appeal is determined.

The High Courts verdict sent shockwaves through the LGBT+ community, as it meant young trans peoples access to healthcare in England and Wales was further restricted.

The case was brought by Keira Bell, 23, who took puberty blockers at 16 and had top surgery at 20 but has since detransitioned, and Mrs A, who is trying to prevent her 16-year-old child taking puberty blockers.

It hinged on whether under-16s can give informed consent to puberty blockers, which are currently the only medication available to trans under-16s experiencing gender dysphoria. Seventeen and 18-year-olds who have been taking puberty blockers for at least a year are eligible for hormone replacement therapy (HRT).

Puberty blockers are widely deemed safe, reversible and medically necessary, lawyers for the Tavistock maintained. Lawyers for Bell and Mrs A argued that trans teens should have to go before a court before being able to access the medication.

The High Court agreed, with the judges saying in their ruling that it is doubtful children aged 14 to 15 could understand the long-term risks and consequences of taking puberty blockers and then HRT, and highly unlikely that children under 13 would be competent to give consent.

As a result, the court said clinicians may regard these as cases where the authorisation of the court should be sought prior to commencing the clinical treatment. The judges ruled that informed consent for puberty blockers should be tied to an understanding of the long-term implications of taking HRT or having gender-affirming surgery later in life.

At the hearing in October, the court heard that in 2019-2020, 161 under-18s were referred by GIDS to be assessed for puberty blockers by endocrinology specialists. Half of the trans youth referred were aged 16 or older even though puberty starts, on average, at age 11 for those assigned female at birth and at 12 for those assigned male.

Years-long waiting lists for GIDS mean trans young people referred to the service wait several years for their first appointment, and must be assessed over at least 10 appointments before being considered for referral on to an endocrinology service to be assessed for puberty blockers.

As a result, many trans teenagers in England and Wales age out of the youth gender clinic system before receiving any healthcare at all.

See the original post here:
NHS wins right to appeal cruel High Court ruling that restricts healthcare for trans kids - PinkNews

Recommendation and review posted by Bethany Smith

Every aspect of our lives has been reconfigured during the pandemic. For many people, this has meant experiencing changes in their gender identity or gender presentation.

Sheryl*, a 30-year-old Brooklyn-based trans woman working in business administration, said she connects the prolonged period of social isolation with her own transition experience a decade ago. For me, in the beginning of my transition, while I was learning how to dress myself and how to safely move through the world, I was treated hatefully for it a lot, she said. I would avoid going out during certain times; I was threatened, harassed, and followed. The amount of trauma... I dont think my brain allowed me to recognize how difficult it was to move through the world at that time. Once I started passing, that didnt happen as much, but my brain will never be able to let go of that when I leave the house. Before [the pandemic], a lot of transexual women were experiencing this, where youre just exhausted by carrying yourself through a world that was not made for you. That ends up translating to spending a lot of time inside.

Dulcinea Pitagora, an NYC-based psychotherapist and sex therapist, suggested that for people working from home, there might be more of a willingness to take risks in terms of gender presentation and expression when interacting with others from the safety of our own space, knowing theres always an option to turn off the screen at any time if we dont feel safe.

That said, not everyone is experiencing positive or affirming changes to their gender because of the conditions created by the pandemic, especially those who feel most affirmed within their communities. Still, many people are taking time to think more deeply about their gender and how it plays out in the world at large, whether that means not shaving for a prolonged period of time, choosing different clothing, or adjusting their pronouns in their Zoom window.

I opened my inbox to people who are experiencing changes in their gender during the pandemic. Here are a few of their stories.

Alex (they/them), nonbinary, 20, white, Ontario, Canada, currently unemployed

Since the pandemic began and Ive mostly been stuck at home with my family, Ive noticed that I have felt less pressure to present myself as feminine. Because Im at home, I can justify wearing clothing that is more gender-neutral or masculine in nature. I suppose the pressure of feeling like I have to present myself a certain way in public because of my assigned gender at birth has been lifted. I cut my hair to a shorter length and dont really care anymore about what gender I appear to be. Im just living as me and Im fine with that.

"I dont want to be male or female, I just wanna be Alex, you know? Plain old Alex."

I began feeling gender dysphoria in high school, and needless to say, it kicked my ass. I despised being female. I had a group of Catholic friends who thought all their problems could be solved by praying to God or Jesus, or whatever. Not to be bitter, I respect peoples beliefs and religious practices, but these friends forced me back into the closet when I opened up to them about my uncertainties surrounding my gender identity. Around this time, I was also forced to come out to my mother because of different circumstances, and she essentially told me to not tell anyone about it and to just go back to being normal. Fun times!

There are days where I fantasize about not having breasts, and there are days where I love my breasts. Same goes with my genitalia. Sometimes I like my vagina; sometimes I wish I had a penis. I wish I could just flip between the two whenever I wanted, while also being considered genderless. I dont want to be male or female, I just wanna be Alex, you know? Plain old Alex.

In a way, the pandemic has been a very, very small positive to me, as it has allowed me to just reflect on myself and come to terms with my identity. If I hadnt literally been forced to stop going out and thus feel the pressure to conform to a certain gender norm, I probably would have taken a lot longer to accept who I am. Of course, now Im ready for the pandemic to be over so I can flaunt my nonbinary ass around in public, but alas, I must wait for that day.

Seven (they/them), nonbinary, 39, Black, Minneapolis, metal fabricator[Since the pandemic began] I started taking T. I've grown some body hair and gained 20 pounds of muscle mass since July. As a queer Black human, I've had to deal with other peoples uncomfortable feelings my whole life. I'm tired. I've known I was nonbinary my entire life but felt as though it wasn't safe to express myself. Dysphoria is sneaky and complicated. I think I spent a good chunk of my life trying to bury it. Honestly, I've felt so at peace internally since I officially came out and started T in July. I finally stopped digging that hole. It's a beautiful thing to finally rest my mind. [Ive talked about these changes with] my wife. I'm kinda letting it present naturally. Changes are happening and people will obviously notice them. How I communicate, love, and go about the world have not shifted.

Without this pandemic and more importantly the civil unrest that ignited through the murder of George Floyd, I would not have truly acknowledged my authentic self. I wouldn't have started on my current path to live the rest of my life unphased by what might make others uncomfortable. With a world of uncertainty, I feel it's time to make the most important things within ourselves certain.

JoAnne (she/her), Delaware, teacher

I was given the name John at birth, but even as a kid, I would refer to myself as JoAnne other than at work. My pronouns were they/them, but this year they are she/her. As soon as I am able to meet with people at work, I will be presenting as female completely.

I live about 30 miles from Philadelphia, in a small college town. Even though we're in the South culturewise, its very LGBTQI friendly. I live with two other people: my wife, who refers to me as her wife, and our boyfriend. We've been a triad for the last five years, and he considers himself as living with two women.

"In other words, there was no reason to be anyone other than JoAnne."

I'm a teacher, college level, and since the pandemic started, I've been teaching remotely. At work I present as male, though that will change in the future, I'm sure. Before the pandemic, I was more gender-neutral, in that I split my time between my male and female sides. At home I was always female but outside the home, with family, I was John. Since the pandemic, I'm 99.9% female. The pandemic, because it enforced certain isolation, gave me the freedom to just stay female to the point where I'm forgetting what it was like to be male. In other words, there was no reason to be anyone other than JoAnne.

I remember a few years ago I was talking to a friend and I broke down crying and just screamed, "I'm the wrong sex." That was the start of a long period of coming to terms with who I am. I confessed to my wife about how unhappy I was and how I felt like I was in the wrong skin. I went to therapy, which helped.

It took the pandemic, really because you're home more and less distracted, to give me time to really work through my gender issues and to work through them with my wife and boyfriend. The good thing is they accept JoAnne and encourage me as I am.

Fanfi (he/she, prefers he), 25, brown/mixed, Santiago, Chile, freelance artist

Im from Santiago de Chile. I live with my nonbinary Venezuelan partner. They have been out since way before the pandemic.

Honestly I didnt feel too strongly about [my gender presentation]. [I used] cis female, woman, or femme at times when I felt particularly lesbian. I am not a woman. I am not a man. I am both a woman and man, only if those are used together. I am a boy, a really pretty one actually. I want to feel masculine. I want to be seen by masculine people who are not cis. Thats what I feel.

"I want to feel masculine. I want to be seen by masculine people who are not cis. Thats what I feel."

I always dyed my hair pink and cut it at a particular queer stylist, but since we were all quarantined, it was closed for months. My hair grew, my color faded, and I started feeling very uncomfortable. I knew I had to make a change so my partner shaved my whole head, and as the layers of hair came off, I saw who I could be: a boy. I didnt know it until I started crying while looking at packers giveaways that were only for trans and nonbinary people when I was cis, but that was the start of it. Now I own a packer that I wear daily if possible, only own a pair of male jeans, and use my partners binder when they arent. Still waiting for mine!

I have a hard time understanding dysphoria. It sounds so terrifying I keep thinking I must not have it, but I also do not have a name for the earth-shattering dread I feel when I try to feel my own vagina. I have never wanted to look at it. I have ignored it most of my life. It felt dreadful wearing a binder the first time too. I thought my tits were gone, and I was scared of [a permanent change]. I feel different about it now, though.

Euphoria I can understand, as I put on my new pair of jeans and read for men on the label, as my friends and partner call me masculine terms of endearment. And I managed to pee standing for the first time! Its great. It makes my day.

Im almost certain I would have kept living as I did were it not for the pandemic. I have a complicated relationship with my mother and immediate family. I try hard to please them. I was always too busy trying to be a pretty woman, to be a lovable, acceptable lesbian for them. The quarantine worked for me as a chrysalis stage: I kept myself still, but so much was happening inside me from this lack of movement. For the first time, I asked myself what I wanted to be without the eyes of others upon me. This was the answer, and its still developing. Its been such a hard year I feel frail and also the happiest Ive been in my body.

Ilde Senescence, she/her/hers, 35, white Jewish trans demigirl

"The pandemic represents about three-quarters of the time I've been on estrogen and progesterone hormone replacement."

The pandemic created conditions for me to be away from contact with (and more importantly the eyes of) most people, [especially] cis people. I had ideal conditions for taking on appearance changes that would otherwise seem drastic, and the space and time to puzzle out my feelings about and understanding of my gender. While this period also included health scares for me, the flexibility of working under pandemic conditions allowed me to recover.

I have grown out my hair longer than it's been in my life and colored it an ombre purple-blue-cyan. I have embraced my emotions and my mood in a way I had not understood prior in the least. The pandemic represents about three-quarters of the time I've been on estrogen and progesterone hormone replacement, so I have seen a number of appearance, functional, and emotional changes simply from that.

My dysphoria has manifested in the past as a fear of not passing, of not feeling my gender intensely or demonstrating it authentically enough, that I wasn't "worthy" of being trans, or that I couldn't present any way other than "diet male." Physically, my body hair has been the primary source of my dysphoria. My biggest sources of gender euphoria have been the changes to my hair, and buying more femme clothes from Torrid, but also in being able to wear a mask and how that has helped me to be passed by cis people in multiple situations.

I have a medium-sized set of trans friends in the area and my roommate. I've talked to them all at length, and we've celebrated each others positive gender feelings due to the pandemic. I also have a psychotherapist who is trans, and with whom I've shared feelings about my transition and the pandemic.

Ezra (they/them), 34, white and Jewish, Chicago, unemployed, former barista

I have worked in the service industry my whole adult life, mostly as a barista. I think Im pretty lucky to have had mostly casual dress codes. Ive only had to take out facial piercings for one place I think, but I never worked anywhere where that relaxed attitude seemed to extend to gender presentation. For three years before the pandemic (and my first three years on T), I worked downtown, and that was probably the most conservative culture Ive worked in. Thats when I had to learn how often I needed to shave my face to pass versus how often I could shave it without leaving the skin raw.

I had been on T for almost three years when the pandemic started, but having been in customer service the whole time, and at the same job since before I started T, I never felt comfortable growing a beard, so I had never seen my facial longer than a few days Id have off for work. So now I have a full beard! Its been really exciting to watch it happen, and now Ive gotten to the point where I feel pretty comfortable trimming it with clippers. Im pretty hairy and I also have big boobs, so when it was hot earlier in the year, doing things like going out in a tank top was a major source of stress for me. I get really hot which makes me really anxious, so Ill do almost anything to stay cool, but going out with size G breasts with lots of chest and shoulder hair makes me feel really nervous. Navigating that felt new this year.

Im so lucky to have many other queer and trans people around me to talk to. A few of my closest friends are trans and/or queer, and I also am part of a group through a clinic that meets virtually once a week to chat about gender stuff. For Thanksgiving, we did a call and I decided to get a little dressed up and I put on makeup, which isnt something I ever really did before I came out, and only a few times since, but I wanted to play with the look of my beard, my mullet, some new long, dangly earrings I got, and makeup. I was excited to do it, and then before the call, I got incredibly nervous! I almost chickened out. But I went through with it, and I got compliments from my friends and it was really affirming, though I was still very ready to get off the phone when it was over because I felt kind of exposed. I dont think I would feel comfortable wearing that out of the house, even if it was just to go to an in-person gender group, and if it wasnt for the pandemic, I wouldnt be Zoom-chatting with people, so I just feel so lucky to have that space to play like that!

As a person whos always worked in customer service, I dont think I could have predicted the positive impacts that isolation would have on my mental health and gender identity stuff. In part because of unconscious trauma patterns as well as gender stuff, my life has always included so much performance, and so going from a stressful home to crappy relationships and the service sector has basically just meant a changing of the audience. For me, stepping into my gender and my identity (and my life) is about making those performances intentional as opposed to defensive and reactionary. With no audience but the one I choose, with my friends over Zoom, my internal sense of who I am has gotten clearer, and the fact that I interact almost exclusively with queer people just feels like it affirms my process as I go. This is certainly not to say that it has all been easy, but as far as the pandemic and isolation goes (and the privilege I have to be able to isolate, of course), I feel its been mostly positive. Of course I miss socializing, but Im kind of a quiet, keep-to-myself, doesnt-like-crowds person to begin with, and Im not really interested in being physically intimate with people, so it may not be as hard for me as for others.

Ive also had a heck of a time sending care packages to my friends through the UPS store thats near my apartment. All of their employees needed some kind of special handling when it came to taking my personal information (my legal first name is Emma) they should probably pay me to train their staff. One guy, who seemed really distressed, decided that someone else, someone named Emma, must have used my account to send a package recently. Sure, dude, whatever.

*Sheryl is a pseudonym.

See original here:
Six Trans People Talk About Their Pandemic Bodies - BuzzFeed News

Recommendation and review posted by Bethany Smith